SHINKEI Therapeutics
Shinkei Therapeutics is a company focused on developing therapies for neurological disorders, with a pipeline of innovative treatments. Their mission is to advance medical solutions for conditions like hyperkinetic movement disorders and traumatic brain injury.
Industries
Nr. of Employees
small (1-50)
SHINKEI Therapeutics
Princeton, New Jersey, United States, North America
Patents
Products
Therapeutic candidate for hyperkinetic movement disorders
Pipeline candidate developed for treatment of hyperkinetic movement disorders (pipeline listing).
Therapeutic candidate for traumatic brain injury
Pipeline candidate developed for treatment of traumatic brain injury (pipeline listing).
Cannabinoid-based combination therapy platform
Platform-level development of combination therapeutics incorporating cannabidiol-based modalities (pipeline listing).
MR-601
A unique combination technology for administration of Cannabidiol at lower dosage levels, improving bioavailability and potentially reducing hepatotoxicity related to higher dosage levels.
MR-201
MR-201 is a novel formulation of a well known NMDA-antagonist being developed for pseudobulbar affect.
MR-301
MR-301 is a novel formulation of a well known NMDA-antagonist developed for the treatment of Traumatic Brain Injury.
Therapeutic candidate for hyperkinetic movement disorders
Pipeline candidate developed for treatment of hyperkinetic movement disorders (pipeline listing).
Therapeutic candidate for traumatic brain injury
Pipeline candidate developed for treatment of traumatic brain injury (pipeline listing).
Cannabinoid-based combination therapy platform
Platform-level development of combination therapeutics incorporating cannabidiol-based modalities (pipeline listing).
MR-601
A unique combination technology for administration of Cannabidiol at lower dosage levels, improving bioavailability and potentially reducing hepatotoxicity related to higher dosage levels.
MR-201
MR-201 is a novel formulation of a well known NMDA-antagonist being developed for pseudobulbar affect.
MR-301
MR-301 is a novel formulation of a well known NMDA-antagonist developed for the treatment of Traumatic Brain Injury.
Services
Engagement for partnerships, licensing, and collaboration opportunities; contact via provided business development email and phone.
Engagement for partnerships, licensing, and collaboration opportunities; contact via provided business development email and phone.
Expertise Areas
- Therapeutic pipeline management
- Neurology therapeutics (movement disorders)
- Traumatic brain injury therapeutics
- Cannabinoid-based therapeutic platforms
Key Technologies
- Cannabinoid combination therapy platforms
- Preclinical-to-clinical therapeutic candidate development
- Portfolio/pipeline presentation and management